Immune-mediated and fibrotic disorders such as eosinophilic esophagitis (EoE) and idiopathic pulmonary fibrosis (IPF) represent complex pathophysiological states characterized by dysregulated inflammation, aberrant immune signaling, and progressive tissue remodeling. Concurrently, patient-centered analgesic strategies, including nitrous oxide use in labor, highlight the importance of experiential outcomes in therapeutic design. Monoclonal antibody therapies like dupilumab, antifibrotic agents such as pirfenidone and nintedanib, phosphodiesterase (PDE) inhibition strategies, and immunomodulatory targeting of innate immune pathways represent convergent paradigms in modern translational medicine.to synthesize pharmacokinetic, pharmacodynamic, immunological, antifibrotic, and experiential evidence across therapeutic domains and construct a unified conceptual framework integrating biologic therapy, small-molecule antifibrotics, immune signaling modulation, and patient-centered analgesia. a comprehensive narrative translational analysis was conducted based strictly on the provided literature. Evidence was integrated across randomized trials, population pharmacokinetic analyses, mechanistic studies, immunogenicity evaluations, inflammatory signaling research, and obstetric analgesia investigations.Dupilumab demonstrates exposure–response relationships across EoE and atopic disease populations, with nonlinear mixed-effects modeling elucidating body weight, age, and immunogenicity influences. Antifibrotic agents pirfenidone and nintedanib target TGF-β, tyrosine kinase signaling, oxidative stress, and fibroblast activation in IPF. PDE inhibition and immune cell crosstalk represent additional therapeutic axes. Nitrous oxide analgesia underscores the importance of patient satisfaction, neurochemical modulation, and safety surveillance. Across domains, immunologic precision, pharmacometric modeling, and experiential medicine converge toward personalized care.Integrating biologic immunomodulation, antifibrotic pharmacotherapy, and patient-centered analgesia reveals shared translational principles: immune pathway specificity, systems pharmacology, exposure–response calibration, and experiential outcomes. These insights support a unified therapeutic paradigm spanning inflammatory, fibrotic, and procedural care contexts.

Dupilumab, Idiopathic Pulmonary Fibrosis, Eosinophilic Esophagitis, Pirfenidone, Nitrous Oxide Analgesia, Immunogenicity, Population Pharmacokinetics

Aoki Y, Nordgren R, Hooker AC. Preconditioning of nonlinear mixed effects models for stabilisation of variance-covariance matrix computations. AAPS J. 2016;18:505–518.

Bai X, Nie P, Lou Y, et al. Pirfenidone is a renal protective drug: mechanisms, signalling pathways, and preclinical evidence. Eur J Pharmacol. 2021;911:174503.

Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488–520.

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–151.

Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 8th ed. Philadelphia: Wolters Kluwer - Lippincott Williams & Wilkins; 2008.

Carstoniu J, Levytam S, Norman P, Daley D, Katz J, Sandler AN. Nitrous oxide in early labor. Safety and analgesic efficacy assessed by a double-blind, placebo-controlled study. Anesthesiology. 1994;80:30–35.

Chehade M, et al. Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age. N Engl J Med. 2024;390:2239–2251.

Chen WC, Yu WK, Vyf S, Hsu HS, Yang KY. Nlrp3 inflammasome activates endothelial-to-mesenchymal transition via focal adhesion kinase pathway in bleomycin-induced pulmonary fibrosis. Int J Mol Sci. 2023;24:15813.

Collado V, Nicolas E, Faulks D, Hennequin M. A review of the safety of 50% nitrous oxide/oxygen in conscious sedation. Expert Opin Drug Saf. 2007;6:559–571.

Coviello A, Iacovazzo C, Frigo MG, et al. Technical aspects of neuraxial analgesia during labor and maternity care: an updated overview. J Anesth Analg Crit Care. 2025;5:6.

Dellon E, Kosloski M, Shabbir A, Glotfelty L, Xu C, Kamal M. Symptomatic improvement in adults and adolescents with eosinophilic esophagitis requires higher systemic dupilumab exposure than histologic response. Clin Transl Gastroenterol. 2025;16:e00793.

Frost EA. A history of nitrous oxide. In: Eger E III, editor. Nitrous Oxide/N2O. New York, NY: Elsevier Inc; 1985:1–22.

Ge ZL, Chen Y, Ma LK, Hu FJ, Xie LB. Macrophage polarization and its impact on idiopathic pulmonary fibrosis. Front Immunol. 2024;15:1444964.

Hirano I, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158:111–122.e110.

Hodnett ED. Pain and women’s satisfaction with the experience of childbirth: a systematic review. Am J Obstet Gynecol. 2002;186:S160–172.

Kamal MA, et al. Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis. Front Immunol. 2024;15:1466372.

Kawamatawong T. Phosphodiesterase-4 inhibitors for non-COPD respiratory diseases. Front Pharmacol. 2021;12:518345.

Ko IG, Hwang L, Jin JJ, et al. Pirfenidone improves voiding function by suppressing bladder fibrosis in underactive bladder rats. Eur J Pharmacol. 2024;977:176721.

Kovalenko P, et al. Exploratory population PK analysis of dupilumab in atopic dermatitis patients and normal volunteers. CPT Pharmacometrics Syst Pharmacol. 2016;5:617–624.

Kovalenko P, et al. Base and covariate population pharmacokinetic analyses of dupilumab using phase 3 data. Clin Pharmacol Drug Dev. 2020;9:756–767.

Kovalenko P, et al. Population pharmacokinetic analyses of dupilumab in adolescents and children ≥6 to <12 years. Clin Pharmacol Drug Dev. 2021;10:1345–1357.

Li Z, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol Drug Dev. 2020;9:742–755.

Lodge K, Nakanishi S, Yazbeck L, Guck J, Molyneaux PL, Cowburn AS. Neutrophils in idiopathic pulmonary fibrosis have a distinct biomechanical phenotype of systemic activation that correlates with disease severity. Poster presented at: A69 Pathogenesis of Interstitial and Pleural Diseases; 2024.

Mansoor E, Cooper GS. The 2010–2015 prevalence of eosinophilic esophagitis in the USA: a population-based study. Dig Dis Sci. 2016;61:2928–2934.

Mrgsolve. Simulate from ODE-based models. 2022.

Nodine PM, Collins MR, Wood CL, et al. Nitrous oxide use during labor: satisfaction, adverse effects, and predictors of conversion to neuraxial analgesia. J Midwifery Womens Health. 2020;65:335–341.

Ogden CL, et al. CDC 2000 growth charts for the United States. Pediatrics. 2002;109:45–60.

Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006;5:949–960.

Richardson MG, Raymond BL, Baysinger CL, Kook BT, Chestnut DH. A qualitative analysis of parturients’ experiences using nitrous oxide for labor analgesia. Birth. 2019;46:97–104.

Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.

Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab in adults and children. Antimicrob Agents Chemother. 2012;56:4927–4936.

Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711–726.

Sun XY, Wang HG, Zhan X, et al. Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis. Front Pharmacol. 2024;15:1256649.

Tiwari P, Verma S, Washimkar KR, Mugale MN. Immune cells crosstalk pathways, and metabolic alterations in idiopathic pulmonary fibrosis. Int Immunopharmacol. 2024;135:112269.

Volmanen P, Akural EI, Raudaskoski T, Alahuhta S. Remifentanil in obstetric analgesia: a dose-finding study. Anesth Analg. 2002;94:913–917.

Wójcik-Pszczoła K, Chłoń-Rzepa G, Jankowska A, et al. A novel pan-PDE inhibitor exerts anti-fibrotic effects in human lung fibroblasts via inhibition of TGF-β signaling and activation of cAMP/PKA signaling. Int J Mol Sci. 2020;21:4008.

Yan LY, Su YF, Hsia I, et al. Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment. Mol Ther Nucleic Acids. 2023;32:36–47.

Yang HZ, Cui B, Liu HZ, et al. Targeting TLR2 attenuates pulmonary fibrosis. J Immunol. 2009;182:692–702.

Yin YQ, Peng F, Situ HJ, et al. Construction of prediction model of inflammation-related genes in idiopathic pulmonary fibrosis. Front Immunol. 2022;13:1010345.